BioAge Labs (BIOA) Corporate presentation summary

Platform and strategy

• Uses a large longitudinal human aging dataset (>150M molecular data points) to identify drug targets for metabolic aging and healthspan extension.

• Validated through ongoing pharma collaborations with Novartis and Lilly, focusing on novel targets and exercise-related healthy aging.

• Board and leadership team includes experienced executives from major pharma and biotech firms, with a track record of clinical and regulatory success.

Lead program: BGE-102 (NLRP3 inhibitor)

• Oral, brain-penetrant NLRP3 inhibitor with a unique, patented binding site and novel mechanism of action.

• Demonstrated best-in-class potency and safety in Phase 1, with >90% IL-1β suppression and 86% hsCRP reduction in obese subjects.

• 93% of obese participants achieved normalized hsCRP (<2 mg/L) after 14 days at 120 mg QD.

• Also reduced IL-6 (58-69%), fibrinogen (30%), and CSF IL-6 (84%) in relevant cohorts.

• Attractive safety profile with only mild/moderate, self-limited adverse events and no dose-limiting toxicities.

Therapeutic focus and clinical development

• Targeting cardiometabolic and neuroinflammatory diseases, including CVD, insulin resistance, MASLD/MASH, neurodegeneration, and ocular diseases.

• Cardiovascular: Normalizing hsCRP via IL-1β suppression can reduce MACE by 25%; oral NLRP3 inhibitors may match injectable anti-inflammatories.

• Ophthalmology: Oral BGE-102 achieves retinal exposure, preserves vascular integrity, and improves insulin sensitivity in preclinical DME models.

• Planned clinical milestones: Full Phase 1 data H1 2026, CV risk Phase 2a results H2 2026, DME Phase 1b/2a initiation mid-2026, results mid-2027.